{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-023060","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.517551+00:00","generated_at":"2026-06-02T00:57:55.373889+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies","bullets":["Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.","Cash, equivalents & short-term investments $161.5M as of Mar 31, 2024, up from $97.7M Dec 31, 2023; includes $86.4M gross from March offering.","IND-enabling studies initiated for ABS-101 (anti-TL1A antibody) in Feb 2024; expects Phase 1 start early 2025, interim data H2 2025.","Anticipates selecting development candidate for ABS-201 (dermatology) in H2 2024; ABS-301 (immuno-oncology) advancing.","Expects to sign at least four drug creation partnerships in 2024; cash runway into H1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-023060","json":"https://secwatch.observer/filing/0001628280-24-023060.json","markdown":"https://secwatch.observer/filing/0001628280-24-023060.md","text":"https://secwatch.observer/filing/0001628280-24-023060.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/0001628280-24-023060-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/absc-20240514.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T00:57:55.373889+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19656aaa3e52fbee02590bcd22d249206dfdf772","claim":"Absci Corp reported the quarter ended March 31, 2024 results: revenue $0.9 million, net income $22.0 million.","evidence_excerpt":"Revenue was $0.9 million for the three months ended March 31, 2024 compared to $1.3 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1672688/000162828024023060/0001628280-24-023060-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Revenue","value":"$0.9 million"},{"label":"Net income","value":"$22.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}